PEMIDX (Pemigatinib)

Pemigatinib is a type of targeted cancer drug. It is a treatment for bile duct cancer that has come back or spread to other parts of the body. This is advanced bile duct cancer. called Fibroblast Growth Factor Receptor 2 (FGFR2).

Cholangiocarcinoma

Indicated for unresectable locally advanced or metastatic cholangiocarcinoma in previously treated patients with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement Each cycle is 21 days 13.5 mg PO qDay for 14 consecutive days followed by 7 days off therapy Continue until disease progression or unacceptable toxicity occurs

Myeloid or Lymphoid Neoplasms

Indicated for relapsed or refractory myeloid/lymphoid neoplasms (MLNs) in adults with fibroblast growth factor receptor 1 (FGFR1) rearrangement 13.5 mg PO qDay Continue until disease progression or unacceptable toxicity occur